top of page

Latest News

Inhalon Biopharma to Provide Update on Inhaled Monoclonal Antibody Therapy Platform at BIO International Convention

Durham, North Carolina, June 3, 2024 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at the BIO International Convention being held June 3-6, 2024, in San Diego, Calif. In his presentation, company CEO John Whelan will discuss the company’s recently announced data on the success of inhaled monoclonal antibodies in treating acute respiratory infections, including a Phase 1b study on IN-006, demonstrating the superiority of inhaled antibody delivery over intravenous (IV) or intramuscular (IM) delivery, and preclinical studies published in Advanced Science and Bioengineering and Translational Medicine.
 
“Amid concerns about emerging pathogens like H5N1, and with lessons learned during the recent COVID-19 pandemic fresh in everyone’s minds, there’s a clear sense that the health care ecosystem needs to be able to quickly develop, manufacture and easily deploy effective treatments for respiratory infections,” said John Whelan, chief executive officer of Inhalon Biopharma. “Our inhaled antibody platform is ideal for this application. We’ve repeatedly shown it to be capable of delivering antibodies directly to the site of infection in the respiratory tract, including the deep lung. Further, because this type of treatment can be administered in a patient’s home, it has the potential to address many of logistical challenges that have hindered access to other antibody-based therapies.” 
 
Inhalon Biophama is developing inhaled antibody products as potential treatments for a range of acute respiratory infections including respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza. This treatment approach involves the delivery of antibody therapy directly to the site of infection, using a handheld nebulizer rather than systemically via an oral or intravenous delivery approach. Such a treatment approach is believed to reduce costs and ease the burden of care on patients and the health care system. 

 

Presentation Details
  Date: June 3, 2024
  Time: 3:15-3:30 p.m. PT
  Location: Company Presentation Theater 3

 

About Inhalon Biopharma

Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC.

 

Contact

For General Inquires

John Whelan

jbwhelan@inhalon.com

 

Media

Gwen Gordon

gwen@gwengordonpr.com

bottom of page